Abbott Shares Slip After Lowered Guidance For 2012

BMI View: Abbott Laboratories has an enlightened appreciation of the two major current trends in the global pharmaceutical market. The US-based company is performing well in emerging markets, where it is increasingly adopting a direct presence, and it acknowledges that developed markets, especially Western Europe, will remain challenging. Aside from Abbott's split into two separate companies later in 2012, investors will be closely following the upcoming release of clinical trial results from the firm's hepatitis C programme and for the chronic kidney disease drug bardoxolone.

To read the full article, please choose one of the following options: